Johnson & Johnson (JNJ) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.

Total Assets Chart for Johnson & Johnson

Johnson & Johnson (JNJ) total assets for FY2025 were USD 199.2B, a 10.6% change from FY2024. Johnson & Johnson's total assets grew from USD 5.1B in 1985 to USD 199.2B in 2025 (3809.8% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 2.6%, 10-year CAGR of 4.1%, 20-year CAGR of 6.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$635.56B
Implied Share Price
$263.73
Enterprise Value
$677.00B
Revenue (TTM)
$97.93B
EBITDA
$34.87B
Profit Margin
21.48%
Trailing P/E
30.81
Forward P/E
21.01
Price/Book (MRQ)
7.63
Price/Sales (TTM)
6.49
EV/EBITDA
19.94
EV/Revenue
6.91
Dividend Yield
2.00%
Book Value
$35.28
Free Cash Flow (FY2025)
$19.70B
Free Cash Flow Yield
3.10%

Snapshot as of 13th October 2026 — not point-in-time controlled, may lag the live market by a few days.